Ved­aBio launch­es with $40M+ in ini­tial fund­ing for CRISPR-based mol­e­c­u­lar de­tec­tion tech­nol­o­gy

Cal­i­for­nia biotech Ved­aBio de­buted on Tues­day with more than $40 mil­lion in ear­ly fund­ing to sup­port its CRISPR-dri­ven mol­e­c­u­lar de­tec­tion plat­form, which it claims could tran­scend the need for tar­get am­pli­fi­ca­tion.

The fundraise was backed by lead in­vestor OMX Ven­tures with help from a hand­ful of fam­i­ly of­fices. Ved­aBio was found­ed by CEO Anu­rup Gan­guli and bio­engi­neer­ing pro­fes­sor Rashid Bashir, who worked to­geth­er at Bashir’s lab at the Uni­ver­si­ty of Illi­nois.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER